New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 24, 2014
05:19 EDTLGND, TGTXLigand signs license agreement with TG Therapeutics for IRAK-4
Ligand Pharmaceuticals (LGND) announced the signing of a license agreement with TG Therapeutics (TGTX) for the development and commercialization of Ligandís Interleukin-1 Receptor Associated Kinase-4 inhibitors. The IRAK-4 program is in preclinical development for potential use in certain cancers and autoimmune diseases. Under the terms of the agreement, Ligand is entitled to receive 125,000 shares of TG Therapeutics common stock, valued at approximately $1M at date of signing, and is eligible to receive $207M in potential milestone payments. Ligand is also eligible to receive tiered royalties of 6% to 9.5% on future net sales of licensed products containing patented IRAK-4 inhibitors.
News For LGND;TGTX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 10, 2014
10:33 EDTTGTXTG Therapeutics price target raised to $33 from $25 at Roth Capital
December 9, 2014
11:15 EDTTGTXTG Therapeutics announces data of TG-1101 in combination with TGR-1202
Subscribe for More Information
December 8, 2014
13:45 EDTTGTXTG Therapeutics says TG-1101 well tolerated in Phase 2 study
Subscribe for More Information
December 7, 2014
16:16 EDTTGTXTG Therapeutics announces results from Phase l study of TGR-1202
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use